Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07387666 | Imaging Acetadote Metabolism in Glioblastoma | EARLY_PHASE1 | NOT YET_RECRUITING | 10 | — | — | Jul 1, 2026 | Jul 1, 2028 | Feb 6, 2026 | 1 | United States |
The effect of Acetadote on glioblastoma metabolism will be assessed by measuring cysteine, glutathione, and lactate in glioblastoma through MRS.
| Arm | Type | Description |
|---|---|---|
| Acetadote 150 mg/kg IV | EXPERIMENTAL | Acetadote will be administered twice during this study: first before undergoing magnetic resonance spectroscopy (MRS) on Day 1 and second before undergoing surgical resection, which will take place between Days 2-21. Acetadote will be administered at a dose of 150 mg/kg IV over 60 minutes. |
| Name | Type | Description |
|---|---|---|
| Acetadote | DRUG | Acetadote 150 mg/kg in 500 cc 5% dextrose IV over 1 hour |
Inclusion Criteria: * 1\. Glioblastoma * 2\. Newly diagnosed with no prior surgery, radiation, chemotherapy, or other tumor-treating agent * 3\. Age ≥18 years * 4\. KPS \> 70 * 5\. Adequate organ and marrow function as defined below: * \- Bilirubin ≤1.5 times upper limit of normal * \- AST and ALT ...